Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
November 6, 2025
Earnings Call Speaker Segments
Lawrence Keusch
executiveHello, everyone, and thanks for joining us on the Teleflex Incorporated Third Quarter 2025 Earnings Conference Call this morning. You can find the press release and the slides that go with this call on our website, teleflex.com. Just a note that a replay is going to be posted on our website as well. If you'd like to listen to that replay, the details are in the press release we issued this morning. On the call with us today are Liam Kelly, our Chairman, President and Chief Executive Officer, along with John Deren, our Executive Vice President and Chief Financial Officer. Liam and John are going to give prepared remarks, and after that, we'll take your questions in a Q&A session. Before we get started, I want to point out that certain topics we'll discuss on this conference call will include forward-looking statements about future events, which are described in the slides posted in the Investor Relations section of the Teleflex website. We want to warn you that these statements are indeed forward-looking by nature and carry risks and uncertainties, so actual events or results could end up differing materially. Among the factors that might lead actual results or events to differ materially are those we reference in today's press release, along with our SEC filings, such as our Form 10-K, which you can access on our website. With that, I'll hand things over to Liam for his remarks.
Liam Kelly
executiveThanks, Larry, and good morning to all of you. I want to start off today by talking about our corporate strategy. To put the company in the strongest possible position to create greater value, we've kept taking bold steps aimed at unlocking value across our business. That includes the separation we previously announced, splitting Teleflex into two standalone companies, RemainCo and NewCo. Consistent with our pledge to deliver the greatest possible value to our shareholders, our board and management team have kept working actively to move forward the process for a possible sale of NewCo, which is now our top priority. Interest in NewCo remains healthy, and we're happy with the momentum and where things stand in the process. After the separation wraps up, each business will be set up in the best possible way for what lies ahead, with sharper strategic focus, simpler operating models, more efficient manufacturing footprints, and capital allocation approaches tailored individually and matched to each one's own growth philosophy and goals. As a reminder, building RemainCo will produce an optimized portfolio centered on three highly complementary units: vascular access, interventional, and surgical. NewCo will be in a position to spot, put money into, and take advantage of opportunities specific to urology, acute care, including intra-aortic balloon pumps and catheters, and OEM end markets. Importantly, our guiding principles remain centered on delivering the greatest value to shareholders throughout this process. If a sale goes through, we plan to use the proceeds to both pay down debt and give capital back to our shareholders. Before I get into our third quarter results, I'd like to give an update on changes to the Italian payback measure. As a reminder, under this measure, when Italian public hospitals spend beyond what the national budget permits on medical devices, manufacturers earning revenue in that country are required to repay part of the excess cost to the government. In June 2025, the Italian government put forward a significant discount under this measure, which took effect in August. The amended law lowered what affected companies, Teleflex included, owed for the years 2015 through 2018. These legislative changes, along with the resulting adjustment to our reserve calculation beyond 2018, produced a $23.7 million decrease in our reserve and a corresponding increase to EMEA revenue for the three and nine months ended September 28, 2025, of which $20.1 million pertains to prior periods. Because the amount tied to prior years doesn't reflect normal revenue adjustments and is non-recurring in nature, we've excluded a $20.1 million increase in revenue related to the prior years from adjusted third quarter 2025 revenue, so that our current operating performance can be evaluated and compared against how we performed in the past. Now, turning to the agenda for the rest of this morning's call, we'll go over the third quarter results, walk through commercial highlights, and finish with our updated financial guidance for 2025. All in all, we're pleased with how we executed in the quarter, with third quarter revenues of $913 million, up 19.4% year-over-year on a GAAP basis. If you leave out the effect from a year ago of the Italian payback measure, adjusted revenues in the third quarter came to $892.9 million. That represents a 16.8% rise compared with the same period last year on a reported basis, and 15.3% higher on an adjusted constant currency basis. During the third quarter, constant currency revenue growth got better sequentially once you set aside the contribution from the acquired vascular intervention business. This comes as we keep pushing for operational excellence throughout our company. Once acquired vascular intervention revenues are excluded, constant currency growth came in at 2.3% versus a year earlier. Adjusted earnings per share for the third quarter reached $3.67, which is 5.2% above the prior year. Let's now go further into how our revenue performed in the third quarter. I'll start by reviewing revenues from our geographic segments in the third quarter. Every growth rate I mention is on a year-over-year adjusted constant currency basis unless I say otherwise, and it takes into account the acquired vascular intervention business. Revenues in the Americas totaled $555.9 million, which is 7.5% higher than a year ago, with the acquired vascular intervention business being the biggest driver of that growth. If you take out the vascular intervention business, growth during the quarter came from strength in our surgical, interventional, and vascular businesses, though this was partly offset by declines in OEM and ongoing difficulties at UroLift. EMEA revenues reached $214.1 million, which is 34.4% above the prior year. Growth in the quarter came from the vascular intervention acquisition business. Once you exclude those acquisition revenues, we saw strength in our surgical, vascular, and interventional businesses, partly offset by our anesthesia business, including lower volume of military orders relative to a year ago. Now let's turn to Asia. Revenues came to $122.9 million, which is 25.3% higher than the prior year, mainly because of the vascular intervention acquisition. During the quarter, we booked a stocking order of roughly $9 million as part of our strategy to grow intra-aortic balloon pump and catheter sales in China. As we expected, volume-based procurement partly offset this. We expect that inventory beyond this $9 million stocking order will be sold through by the close of 2025 as tariff-related dynamics settle down, including the timing of orders and tender activity. Let's now discuss our third quarter revenues by global product category. Comments on global product category growth for the third quarter are also on a year-over-year adjusted constant currency basis unless otherwise stated. Beginning with vascular access. Revenue rose 4.3% from a year earlier to $191 million, driven by our wide vascular access portfolio, including peripheral access, EZ-IO, and central access products. Turning to interventional. Revenue was $266.4 million. That's a rise of 76.4%. If you exclude the effect of the vascular intervention acquisition, interventional revenues grew 9% compared with the prior year. Strong performance in the quarter was led by growth drivers including intra-aortic balloon pump catheters, uncontrolled, and complex catheters. Revenue from the acquired vascular intervention business came in slightly above our $99 million forecast for the third quarter and rose 6.9% from a year earlier on a reported basis. We remain confident in our vascular intervention guidance of $204 million in revenue for the second half of 2025. In the third quarter, our intra-aortic balloon pump revenue growth fell compared to a year ago, driven by order rates coming in below what we expected, mainly within the United States. To be specific, we're observing a deceleration in convergence for pumps within the annual replacement cycle, plus reduced activity among hospital systems when it comes to swapping out complete fleets of pumps. While we had expected this dynamic to play out in 2026, it happened earlier than we anticipated. Consequently, at the midpoint of our constant currency guidance, we've reduced our 2025 global balloon pump revenue expectations by $30 million, and the United States accounts for the vast majority of that reduction. Even with this revised outlook for pump demand in the second half of 2025, we've gained considerable market share and improved our overall market position starting in the fourth quarter of 2024. Now turning to anesthesia: revenue dropped 1.4% to $101.4 million. Lower military orders and weakness in tracheostomy tubes were partly offset by growth in ET tubes and LMA single-use masks, together with a double-digit rise in hemostatic products in the United States. Over in our surgical business, revenue reached $122.9 million, up 8.8%.
Liam Kelly
executiveWhen we examine the fundamental patterns within our primary surgical segment, performance stayed robust. Chest drainage along with instrumentation drove most of the quarterly expansion, although the planned impact of China's volume-based procurement partially counterbalanced that. Volume-based procurement has no impact on our surgical operations in North America and EMEA, and both achieved double-digit increases during the period. Turning to interventional urology, we generated $71.8 million, representing a 14.1% decrease. Barrigel delivered notable double-digit expansion, yet UroLift continues to face considerable headwinds. OEM revenue declined 3.9% compared with the same period last year, landing at $80.4 million, which reflects customer inventory management. Even so, we did post a quarter-over-quarter revenue gain, in line with what we had anticipated. Third-quarter revenue from other sources came in at $59 million, up 3.1%. Gains during the period were spread broadly throughout the portfolio, and that concludes what I have to say regarding our revenue results for the third quarter. Turning now to updates on the clinical and commercial side. Our European randomized control trial for the Freesolve resorbable magnesium scaffold, known as BIOMAG-II, reached its midpoint earlier than planned, and enrollment has now passed 1,000 patients. BIOMAG-II is a prospective, multicenter randomized control trial intended to assess how safe Freesolve is and how it performs clinically when compared with a contemporary drug-eluting stent. Target lesion failure rates at 12 months serve as the primary endpoint, and we continue to expect data from the BIOMAG-II study to be read out in 2027. Work on combining the vascular intervention business we bought is moving along nicely and is where we expected it to be. As we shared in today's press release, we have a restructuring plan that's meant to bring costs down and make operations more efficient, and it involves cutting jobs and moving some manufacturing to lower-cost sites we already have; our expectation is that these restructuring steps will be mostly finished by the close of 2028. Over in interventional urology, we brought Barrigel to Japan in the third quarter after it received regulatory clearance, secured insurance reimbursement, and had appropriate use criteria published. Bringing Barrigel to the Japanese market is a major step in rolling the product out worldwide; back in 2022, prostate cancer ranked as the top cancer affecting men, with more than 104,000 newly diagnosed cases. With the introduction of Barrigel in Japan, our goal is to give men a safer and more accurate treatment choice while improving life quality for prostate cancer patients who receive radiation therapy. Thanks to Barrigel's greater precision and sculpting capability, placement can be guided by real-time ultrasound and customized for each individual. Efficacy is backed by U.S. clinical data, which demonstrated that 98% of patients saw a meaningful decrease in radiation exposure to the rectum. Compared with control, the spacer has also been shown to significantly lower both acute and long-term grade 1 plus GI toxicity at three and six months. The first procedures in Japan took place in early August, and we are actively working with Japanese clinicians through training programs to ensure the technology is adopted effectively. That wraps up what I had prepared to say. At this point, I'd like to hand things over to John, who will walk us through the third quarter's financial results in greater detail. John.
John Deren
executiveThank you, Liam, and good morning to everyone. Building on what Liam covered and how the company's top line has performed, I'd like to start with margins. Adjusted gross margin came in at 57.3% for the quarter. That 350 basis point drop compared with a year ago stemmed mainly from tariffs and foreign exchange rates both weighing negatively, and to a smaller degree from product mix along with higher logistics and distribution costs. In the third quarter, adjusted operating margin reached 23.3%. That 400 basis point drop reflects pressure on gross margin compared with a year ago, along with higher operating costs from acquiring the vascular intervention business. Those factors were partly offset by expense discipline across the remainder of our operations, as well as the negative impact of foreign exchange rates. For the third quarter, adjusted net interest expense was $29.7 million, compared with $18.8 million during the same period a year earlier. The increase from last year mainly stems from debt we took on to finance the vascular intervention acquisition. In the third quarter of 2025, our adjusted tax rate was 9.1%, compared with 13.6% in the prior year period. Most of that drop compared with a year ago comes from favorable tax provisions in the One Big Beautiful Bill Act, which was passed recently — for example, being able to deduct R&D expenses based in the U.S. — plus some other discrete items in the quarter that won't repeat. Turning to the bottom line, adjusted earnings per share in the third quarter came to $3.67. That figure rose 5.2% from a year earlier, driven mainly by greater revenue and adjusted operating income, which includes the effect of the vascular intervention acquisition, as well as a lower tax rate and fewer shares, with those gains partly canceled out by negative effects from interest expense and foreign exchange. Let me now move on to a handful of balance sheet and cash flow points. Operational cash flow came in at $189 million across the nine-month span, versus $435.6 million during the same stretch a year earlier. That $246.6 million drop stemmed largely from negative working capital movements, plus the previous year's influx of proceeds tied to ending the pension plan. The adverse working capital shifts mostly involved the vascular intervention acquisition, tariff-related disbursements, outlays connected to the proposed separation, cash tax payments for the final transition payment under the TJC Act of 2017, and foreign tax payments tied to restructurings from earlier periods. Now turning to the balance sheet. When the third quarter wrapped up, the balance for our cash along with cash equivalents and restricted cash equivalents came to $381.3 million. That compares with $327.7 million at the close of 2024. Net leverage stood at roughly 2.4x when the quarter ended. Now let's move to our revised financial guidance for 2025. For the full year 2025, we're anticipating total adjusted constant currency growth landing somewhere between 6.9% and 7.4%. This projection takes into account how we performed across the first three quarters and our refreshed outlook for the fourth quarter of 2025. We lowered our constant currency revenue outlook, and the main reason is that we're now assuming less intra-aortic balloon pump revenue, largely in the U.S. That change applies to the back half of 2025, since we expect order rates to stay below what we had anticipated all the way through Q4. On the foreign exchange side, our view has gotten better — we now see a positive $32 million, which translates to about a 100 basis point lift to GAAP revenue growth in 2025. Before this, our guidance was roughly $26 million, equal to an 85 basis point tailwind for 2025. Embedded in the updated FX guidance is an average euro rate of approximately $1.16 for Q4 2025. When it comes to 2025, adjusted revenue growth is now projected at 8%-8.5%, compared with the 8.5%-9.5% we guided to before. That translates into revenue dollars of $3.305 billion-$3.320 billion. This adjusted revenue range serves as the anchor for our 2025 guidance and reflects the acquired vascular intervention business, Q3 performance, revised Q4 expectations and FX rates, while leaving out the $20.1 million positive revenue adjustment tied to the Italian payback measure for prior years. Under GAAP, revenue growth should come in at 9.1%-9.6%, including that $20.1 million revenue benefit from the Italian payback measure for prior years. There are also a few things to keep in mind for modeling purposes. We anticipate 2025 adjusted gross margin of roughly 59%. On tariffs, I'm happy to say our mitigation strategies made solid headway during the third quarter. Thanks to changed rate assumptions and mitigation efforts, our 2025 estimate is now $25 million-$26 million, or about $0.50 per share, an improvement over the $29 million, or $0.55 per share, we previously estimated for 2025. Adjusted operating margin should land at about 24.5%. Now for items below the line. Net interest expense for 2025 is now anticipated at $93 million; we've also fine-tuned our 2025 tax assumption and now forecast a tax rate of roughly 12.5%, compared with the 13.25% we expected previously. As for adjusted earnings per share, we're tightening the 2025 range to $14-$14.20, down from $13.90-$14.30. In the fourth quarter, adjusted constant currency growth should fall between 14%-15.8%, before an FX benefit of about $21 million. That wraps up my prepared remarks, and I'd like to hand the call back to Liam now for some closing commentary.
Liam Kelly
executiveThank you, John. To wrap up, I'd like to emphasize three main points from Q3 of 2025. To begin, we kept making substantial headway when it comes to carrying out our strategy. Revenue for the third quarter landed within the guidance range, yet operating margin and earnings per share came in above what we had anticipated. When it comes to RemainCo, the results across the opening nine months of 2025 have pleased us, and that bodes well for our growth prospects over the longer term. Next, our vascular intervention business delivered a solid quarter, posting reported revenue growth of 6.9% versus a year earlier, which was slightly ahead of our guidance. We look forward to sharing a fuller picture of the vascular intervention business during a virtual investor meeting set for November 14th at 8:00 A.M. Eastern Time. You can find registration information in the press release we put out on October 16th. Finally, we stay sharply focused on managing the things within our control throughout the business as we keep pushing our strategic objectives forward. We're concentrating on improving how we execute operationally, speeding up growth, and bolstering our varied product portfolio so we can serve our customers better; we're happy with how the separation of Teleflex is progressing, including giving priority to a possible sale of NewCo, since interest continues to be strong. Our core principles stay centered on getting the most shareholder value out of this process. That brings my prepared remarks to a close. At this point, I'd like to hand the call back to the operator so we can move into Q&A.
Mike Matson
analystYeah. Appreciate you fielding these. I suppose I'll begin with what was said regarding balloon pumps in China. That part didn't fully land with me. Could you expand on it a bit further?
Liam Kelly
executiveYeah, of course, Mike. During the quarter, we observed a stocking order worth roughly $9 million placed by certain distributor customers of ours. There are essentially two explanations for that. First, since we're carrying out our intra-aortic balloon growth strategy aimed at reaching more of the geographic market. Right now, Mike, roughly 30% of the market is covered by us; this expansion has partly come about because of government changes, which recommend the use of intra-aortic balloon pumps and catheters for complex PCI procedures. The second explanation, Mike, involves a bit of noise surrounding tariffs in the market, and that has pushed customers to change their behavior, buying product ahead of tariffs while tenders get delayed to later in the year. We anticipate this will normalize in Q4 as we sell through this inventory and even some additional out through the channel as we get these tenders in. It's a timing matter in Q3, which is why I wanted to call it out for clarity.
Mike Matson
analystAll right, understood. We came across some TCT data regarding drug-coated balloons, and I realize the BIOMAG trial with your resorbable stent is currently running, though those results won't be available until 2027. When it might get approved in the U.S., I have no idea. Could there be a danger that you give up some portion of your share in the legacy stent and balloon segment to these more recent drug-coated balloons in the U.S. and Europe, whether from Boston Scientific or Quartus? Also, perhaps you could tell us what portion of the vascular intervention business you purchased is focused on PCI rather than peripheral? Thanks.
Liam Kelly
executiveYes. Appreciate the question, Mike. We'll probably address that in greater depth at our investor meeting next week. What I can say is that concerning how our drug-coated stents performed during the quarter, it matched expectations; no impact is showing up. I'd also like you to keep in mind that in Europe, drug-coated balloons have been available for far longer than in the U.S. With the technologies you're referring to, you still observe, alongside those technologies, drug-coated stents continuing to be utilized. Clearly, given BIOTRONIK is expanding at a rate of almost 7%, that's quite encouraging for the business we recently acquired, Mike.
Matt Taylor
analystOh, my apologies for that. Hello. Thanks for taking my question. I suppose I was hoping you might be able to say a bit more. From what the press release appeared to indicate, a sale is now the main priority for NewCo. Has the spin-off been ruled out? I guess, could you discuss the reason you're leaning so heavily toward selling? Do you believe you could potentially sell this at a valuation that's accretive? Thanks.
Liam Kelly
executiveYes. Thank you, Matt. Matt, as I mentioned during my prepared comments, consistent with our pledge to deliver maximum value to shareholders, both our board and management team have acted decisively and are pushing the potential NewCo sale process forward aggressively. Sitting here right now, Matt, I feel good about how far we've come and where we stand regarding the separation; the caliber and sheer number of interested buyers keeps making an impression on us. Regarding what you asked about valuation, from where we sit, that reflects how strong the assets inside NewCo really are. During our Q2 earnings call, we talked about having held early-stage meetings with numerous prospective purchasers who had shown interest in buying NewCo. From that point on, we've been moving the possible sale of NewCo ahead energetically. The momentum has carried on, we've pushed things to advanced diligence stages, and we're confident about our capacity to deliver maximum shareholder value while making the NewCo sale our top focus. On the latter portion of what you asked — is spinning off still an option? Again, I'd say we remain happy with our progress and our current position. A spin still looks like a chance to create shareholder value, yet given how much interest and momentum the NewCo sale now has, that has become our top priority, and we're carrying it out. Let me also touch on RemainCo, Matt, and add a bit more about how it did across the opening 9 months. Constant currency revenue growth for the year so far, through those first 9 months, came in at roughly 5% versus a year earlier, once you strip out the vascular intervention business we acquired along with the negative effect of volume-based procurement, which we recognize is temporary. That's a positive sign and fits precisely within our mid-single-digit growth range.
Jayson Bedford
analystMorning. This one's probably for John. John, plenty of growth rates got mentioned, and I'm much slower these days than I once was. How many dollars does the fourth quarter revenue guidance come to? I'll go ahead and put my second question out there while you maybe look that up, John. Turning to the spin and the sale — the business has shifted somewhat since the last time you gave us details on RemainCo and NewCo regarding margins. Could you possibly give us an update on margins, the range, and tariff exposure for those two businesses? Thanks.
Liam Kelly
executiveOn the growth side, the largest effect in Q3 — well, let me start by saying Q3 performance made me happy. We carried things out well during the quarter, and we hit our commitments even with the softness in intra-aortic balloon pumps, which surgical strength made up for. Clearly, the BIOTRONIK VI business we just acquired did extremely well during the quarter. As for RemainCo and NewCo margins, nothing meaningful has shifted in either one apart from what tariffs have done. When we consider the tariff effect, I believe the prospective purchasers of NewCo have had that information shared with them, so they know all about it. The pump effect has been shared with the buyers too, so they know all about it. We included quite a bit of tariff detail in our prepared remarks, along with the decrease in what we anticipate for this year. Tariffs, at least, are in a somewhat better and more settled environment, I'd say. I'll have John take your first question.
John Deren
executiveRight. For Q4, the guidance works out to between $930 million and $945.6 million in dollar terms. That represents growth of 14% to 15.8% on a constant currency basis. And within that, we're looking at roughly a $21 million benefit from foreign exchange.
Ravi Misra
analystMorning, everyone. Ravi speaking, filling in for Rich. I appreciate you taking my question. Liam, I've got one to kick things off, then something else after. Regarding the vascular segment you're reorganizing — there's a rather large new product trial currently running. I'm wondering — and I hope I'm not taking away anything from the analyst presenting later today — do you actually require additional marquee offerings within this unit to genuinely speed up expansion on top of that $1 billion revenue foundation you currently hold? Any perspective on that would be welcome. One more thing after. Thanks.
Liam Kelly
executiveYes. Thank you, Ravi. To be clear, what you're referring to is our interventional business. Let me begin by noting it's merely a single quarter, yet it's a quite promising beginning for BIOTRONIK, with growth near 7%. Straight away. That exceeded our expectations, so we're pleased with it. When examining the organic expansion during the quarter for the interventional unit, as mentioned during our prepared remarks, once you set aside the BIOTRONIK VI acquisition, growth was approximately 9%. Its performance is extremely strong. A range of fresh offerings is entering the portfolio within that unit so we can keep speeding up expansion. Within RemainCo, the interventional business is going to serve as a powerful engine, and we expect it to land at the higher portion of that mid-single-digit range we referenced. In my view, no extra flagship offering is required for us to hit our targets. Numerous products are slated for introduction into the portfolio. We'll be pushing investment toward this unit to broaden it and expand it, plus we'll put money into R&D. M&A represents a potential future avenue for this unit. For Teleflex, I believe it matters that we deliver as we move through 2026, validate our thesis across 2026, produce those mid-single digits, and restore confidence in the stock.
Ravi Misra
analystThanks. I just have a question about the tightening going on right now. During the past two quarters, your remarks acknowledged the difficulties in bariatrics, yet that seemed to be a product performing rather well — at least the stapling system did, from our perspective. How should we consider the possible growth rate for that business going forward, as far as the segment is concerned? Thank you.
Liam Kelly
executiveYes, Ravi, the growth rate I can provide for the quarter sits in the upper single digits. This product continues to expand, and we expect expansion in the future as well. I'll have John address the restructuring, but ultimately, the base is smaller despite the growth, and that has created some pressure and led to the write-down; John, would you like to go ahead?
John Deren
executiveRight. I mean, I’m not going to go deep into the GAAP technical side, since this concerns intangible assets, and that’s somewhat distinct from a goodwill impairment. But the point is that the near-term outlook clearly carries through into the longer-term projections. And although GLP-1s continue to place substantial pressure on this product, as Liam mentioned, it is still growing. It’s simply not expanding at the pace that had been part of our initial plan and at the time we completed the acquisition. So regrettably, a write-down on these intangibles was necessary.
Samantha Munoz
analystHello there, and good morning. Samantha here, filling in for Matt today. We really appreciate you giving us the chance to ask. I suppose, could you share a bit more about the possible NewCo sale? It sounds as though talks might be fairly far along with a single prospective buyer, or perhaps several, and also whether the plan remains to sell NewCo in its entirety, or instead in pieces.
Liam Kelly
executiveDetails about how many buyers there are, or anything along those lines — I won't be going into that. What I can say is that our aim is to sell NewCo as a whole; our progress has been substantial. Believe me, we haven't been idle. Toward that final objective, we've been putting in relentless effort. Due diligence is now at a later stage. With several buyers, I can tell you, due diligence is at a later stage as we begin moving this forward. On the second quarter earnings call, I laid out that preliminary meetings had taken place. After that, we held quite a few meetings, performed a great deal of due diligence, examined the business in depth, and kept up continuous discussions with more than one buyer. Our view — and we've carried out an enormous amount of analysis on this, externally as well as internally — is that our guiding principle of maximizing shareholder value is best achieved right now by way of an exit through a sale. For our shareholders, we believe that represents the optimal result, which is why, at this moment, we're giving priority to the sale rather than the spin.
Samantha Munoz
analystGreat. Thanks a lot. If I could just squeeze in one more about the intra-aortic balloon pumps. I realize you mentioned this had been anticipated for next year but got moved up somewhat. Could you expand a bit on what the longer-term picture looks like for those products, and then in particular, for how long a period might the catheters sold alongside them keep serving as a growth driver?
Liam Kelly
executiveYeah. Samantha, that's a terrific question. I mean, I think if we simply step back and remind everybody, this is a $250 million annual market split between pumps and catheters. We started out with roughly a third of the market share, under a third in the United States, and over a third overseas in Asia. We were capturing meaningful share before the competitor issue, with the business expanding organically, strong double digits. Customers started swapping out their pumps because of the FDA notice. We also witnessed pull forward in conversions, which enlarged the market over this period. We carried out that strategy well. Even with the bolus that we picked up in Q4 2024, we delivered $70 million in Q4, which was significantly up from 2023; this year, it should be in the United States, these numbers are, it should be around $80 million this year in the United States; we generated really strong growth in the first half of 2025, and we expected that growth rate to persist into the back half. Conversions have slowed earlier. We thought it would happen in 2026. We were expecting this to be a little bit of an overhang in 2026. Our change in assumption is just as a result of the conversions happening earlier than we had anticipated. On your question about catheter, we would anticipate catheter growth to be with us for the last number of years. In Q3, I mean, the catheters grew strong double digits in Q3. Obviously, we've increased our market share in the United States fairly significantly during that time.
Patrick Wood
analystHi, everyone. I really appreciate you fielding this. I'll kick things off with something a bit out of left field. Regarding the BIOTRONIK vascular unit, it's clearly encouraging to watch it perform well. What's the situation with keeping staff there? In what ways have they been merging in? Were you able to retain those people? Really, it's the softer, more qualitative aspects of how that process is unfolding.
Liam Kelly
executiveYes. Thank you, Patrick. So, things are going quite smoothly with the integration. In my view, the folks at BIOTRONIK VI, now that they're under the Teleflex umbrella, perceive a considerably larger interventional portfolio. After all, we're on track toward a billion dollars in the interventional business. For RemainCo, this comes with a fantastic growth trajectory. When it comes to retention, it's been extremely stable. Throughout this process, not a single member of the senior leadership has left us, and that gives me a lot of confidence. The team is strong, particularly when you look at technical and R&D expertise. I've visited them on multiple occasions, and each time I spend time with them, their R&D skills and the innovation this group is capable of delivering never fail to impress me.
Patrick Wood
analystThat's really useful. Just a quick one — clearly, procedure volumes remain very robust, and on top of that, we're watching a lot of additional procedures shift into the cath lab that perhaps previously weren't performed there. You have an extremely wide-angle perspective on the entire system. What's your sense of volumes, both within the cath lab and beyond it, plus how healthy the market looks from a procedural angle too?
Liam Kelly
executiveYes, that's an excellent question. So when I look at BIOTRONIK's 7% growth, and when I consider how our interventional business excluding BIOTRONIK VI is expanding at 9%, one thing becomes obvious: the cath lab is in a really strong position at the moment, fueling nice, dependable upper single-digit expansion across the portfolio we have today. In that space, procedures are holding steady or getting better. A great deal of technology keeps flowing into that space; for our part, we appreciate the optionality of what we'll deliver with Freesolve down the road, and we want to take part in that and leave nothing behind; in a couple of weeks, we're eager to walk the investment community through how the BIOMAG study is progressing. Yes, Patrick, that's how I'd characterize it — quite stable, with nice, dependable growth emerging from the cath lab area.
Liam Kelly
executiveYeah. It’s still early. Aiden, to give you a clear sense of whether synergies are showing up yet in the sales force. We’ve seen a few anecdotes, but I don’t want to label that a trend yet, where certain complex catheters of ours and certain stents and balloons of theirs have been pulled in and paired, with a number of users quite excited at TCT; when it comes to the portfolio as a whole; when it comes to integration and restructuring, much of that sits in what I’d describe as back-office functions, which is where the synergies are being generated. The integration, clearly. Some will certainly be in the commercial organization, but I don’t want to go into further specifics about that on this call.
Lawrence Keusch
executiveAppreciate that, Kayla. And thanks as well to all of you who took the time to be with us on today's call. That wraps up the Teleflex Incorporated Third Quarter 2025 Earnings Conference Call.
Operator
operatorYou may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.